trial

Clinical Trial of AVL-3288 in Schizophrenia Patients

NCTId NCT02978599
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 24 (actual)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2018-10-26
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
24 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2016-11
Primary completion
2018-10-26
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
AVL-3288

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Jeffrey A. Lieberman, MDPrincipal Investigator

Sites

1 total
New York, United States

Facts & assertions

4 sourced
Enrollment
24
Phase
PHASE1
Primary Completion Date
2018-10-26
Status
COMPLETED
relationships
The graph out of here
drug
AVL-3288
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Jeffrey A. Lieberman, MD
person